Is Amphastar Pharmaceuticals Mispriced After a Tough Year and Promising Cash Flow Outlook in 2025?

Simply Wall St.12-10

Wondering if Amphastar Pharmaceuticals is a bargain after its rough patch, or if the market sees something you do not? Let us unpack what the current share price might really be telling you about its ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590540584?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2025-12-10 18:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590540584","market":"us","top_or_hot":-1,"title":"Is Amphastar Pharmaceuticals Mispriced After a Tough Year and Promising Cash Flow Outlook in 2025?","media":"Simply Wall St.","content":"<div>\n<p>Wondering if Amphastar Pharmaceuticals is a bargain after its rough patch, or if the market sees something you do not? Let us unpack what the current share price might really be telling you about its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amph/amphastar-pharmaceuticals/news/is-amphastar-pharmaceuticals-mispriced-after-a-tough-year-an\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Amphastar Pharmaceuticals Mispriced After a Tough Year and Promising Cash Flow Outlook in 2025?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Amphastar Pharmaceuticals Mispriced After a Tough Year and Promising Cash Flow Outlook in 2025?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-10 18:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amph/amphastar-pharmaceuticals/news/is-amphastar-pharmaceuticals-mispriced-after-a-tough-year-an><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wondering if Amphastar Pharmaceuticals is a bargain after its rough patch, or if the market sees something you do not? Let us unpack what the current share price might really be telling you about its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amph/amphastar-pharmaceuticals/news/is-amphastar-pharmaceuticals-mispriced-after-a-tough-year-an\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4557","symbol_name":"大麻股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amph/amphastar-pharmaceuticals/news/is-amphastar-pharmaceuticals-mispriced-after-a-tough-year-an","article_id":"2590540584","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amph/amphastar-pharmaceuticals/news/is-amphastar-pharmaceuticals-mispriced-after-a-tough-year-an","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2590540584","pubTimestamp":1765361933,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Wondering if Amphastar Pharmaceuticals is a bargain after its rough patch, or if the market sees something you do not? Let us unpack what the current share price might really be telling you about its long term value.\nThe stock has slipped 3.8% over the last 7 days, but it is up 6.7% over the past month and still down 29.5% year to date and 41.2% over the last year. This profile hints at both recovery potential and lingering skepticism.\nRecent headlines around Amphastar have focused on its...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4557":"大麻股","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","AMPH":"Amphastar Pharmaceuticals","BK4007":"制药","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Amphastar Pharmaceuticals在经历了艰难的一年和2025年充满希望的现金流前景之后是否定价错误？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"AMPH":1.5},"content_text":"Wondering if Amphastar Pharmaceuticals is a bargain after its rough patch, or if the market sees something you do not? Let us unpack what the current share price might really be telling you about its long term value. The stock has slipped 3.8% over the last 7 days, but it is up 6.7% over the past month and still down 29.5% year to date and 41.2% over the last year. This profile hints at both recovery potential and lingering skepticism. Recent headlines around Amphastar have focused on its injectable and intranasal drug portfolio expanding into more specialized hospital and emergency care use cases, alongside continued attention on the company as a niche player in complex generics. This kind of product and pipeline narrative helps explain why the stock has seen bouts of renewed interest even after a tough year on the charts. Despite the volatility, Amphastar currently scores a strong 6/6 valuation check score, suggesting the shares look undervalued across all our standard tests. Next, we will walk through those methods while also exploring a more complete way to think about what the business is really worth.  Find out why Amphastar Pharmaceuticals's -41.2% return over the last year is lagging behind its peers. AdvertisementApproach 1: Amphastar Pharmaceuticals Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model estimates what a company is worth by projecting the cash it can generate in the future and discounting those cash flows back to today. For Amphastar Pharmaceuticals, the model uses a 2 Stage Free Cash Flow to Equity framework, starting from its last twelve months Free Cash Flow of about $110.7 Million. Analysts and internal estimates see Amphastar’s Free Cash Flow rising steadily, with projections reaching roughly $218.8 Million by 2035. Early years are based on analyst forecasts, while later years are extrapolated using modest growth assumptions by Simply Wall St to avoid overly aggressive expectations. All of these future cash flows are then discounted to reflect risk and the time value of money. Putting these projections together, the DCF model suggests an intrinsic value of about $97.29 per share, implying the stock is trading at a 73.6% discount to its estimated fair value. That indicates a wide margin of safety if Amphastar can deliver on even a conservative version of these cash flow expectations. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Amphastar Pharmaceuticals is undervalued by 73.6%. Track this in your watchlist or portfolio, or discover 895 more undervalued stocks based on cash flows. AMPH Discounted Cash Flow as at Dec 2025 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Amphastar Pharmaceuticals. Approach 2: Amphastar Pharmaceuticals Price vs Earnings For a profitable business like Amphastar Pharmaceuticals, the price to earnings, or PE, ratio is a practical way to gauge how much investors are paying for each dollar of current earnings. In broad terms, companies with stronger growth prospects and lower perceived risk can justify a higher PE, while slower growth or higher uncertainty usually warrant a lower one. Amphastar currently trades on a PE of about 10.6x, noticeably below both the broader Pharmaceuticals industry average of roughly 19.2x and the peer group average of about 23.2x. Simply Wall St also calculates a Fair Ratio of 15.9x. This represents the PE multiple the stock might reasonably command once you factor in its earnings growth outlook, profitability profile, market cap, industry positioning and specific risks. This Fair Ratio framework goes beyond a simple comparison with peers or sector averages by tailoring expectations to Amphastar’s own fundamentals rather than assuming it should trade like a typical pharma stock. With the Fair Ratio of 15.9x sitting well above the current 10.6x multiple, the PE analysis points to Amphastar being undervalued on an earnings basis. Result: UNDERVALUED NasdaqGS:AMPH PE Ratio as at Dec 2025 PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1450 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Amphastar Pharmaceuticals Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple framework that lets you write the story behind your numbers by linking your view of Amphastar’s future revenues, earnings and margins to a concrete financial forecast and, ultimately, a fair value estimate. On Simply Wall St’s Community page, used by millions of investors, Narratives are an easy, guided tool where you spell out your assumptions, see how they translate into forecasts, and then compare your resulting Fair Value with today’s share price to decide whether Amphastar looks like a buy, hold or sell for you. Because Narratives automatically update as new information such as earnings releases, product news or industry shifts comes in, your fair value view stays live and responsive instead of static. For example, one Amphastar Narrative might lean cautious, focusing on intensifying generic competition and landing near the low end of analyst fair values around 25 dollars. In contrast, a more optimistic Narrative could emphasize pipeline progress, domestic capacity and higher margins to justify a target closer to 38 dollars. Do you think there's more to the story for Amphastar Pharmaceuticals? Head over to our Community to see what others are saying! NasdaqGS:AMPH 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590540584","isCrawlerRequest":true}